tiprankstipranks
Innovent Biologics (IVBXF)
OTHER OTC:IVBXF
Holding IVBXF?
Track your performance easily

Innovent Biologics (IVBXF) Income Statement

31 Followers

Innovent Biologics Income Statement

Last quarter (Q2 2022), Innovent Biologics's total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, Innovent Biologics's net income was ¥―. See Innovent Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-¥ 4.27B¥ 3.84B¥ 1.05B¥ 9.48M¥ 18.54M
Cost of Revenue
-¥ 573.04M¥ 387.76M¥ 124.88M¥ 0.00-
Gross Profit
-¥ 3.70B¥ 3.46B¥ 922.65M¥ 9.48M-
Operating Expense
-¥ 6.05B¥ 3.50B¥ 2.20B¥ 1.56B¥ 643.27M
Operating Income
-¥ -2.35B¥ -42.44M¥ -1.28B¥ -1.55B¥ -624.73M
Net Non Operating Interest Income Expense
-¥ 89.29M¥ 47.75M¥ -59.49M¥ -48.29M¥ -49.24M
Other Income Expense
------
Pretax Income
-¥ -3.05B¥ -858.71M¥ -1.72B¥ -5.87B¥ -716.05M
Tax Provision
-¥ 87.04M¥ 139.71M¥ 0.00--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-¥ -3.14B¥ -998.42M¥ -1.72B¥ -5.77B¥ -562.32M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-¥ 6.62B¥ 3.89B¥ 2.33B¥ 1.56B¥ 643.27M
Net Income From Continuing And Discontinued Operation
-¥ -3.14B¥ -998.42M¥ -1.72B¥ -5.77B¥ -562.32M
Normalized Income
-¥ -3.23B¥ -1.02B¥ -1.72B¥ -1.44B¥ -549.51M
Interest Expense
-¥ 62.46M¥ 68.35M¥ 59.49M¥ 68.97M¥ 57.23M
EBIT
-¥ -2.99B¥ -790.36M¥ -1.66B¥ -5.80B¥ -658.83M
EBITDA
-¥ -2.78B¥ -704.74M¥ -1.57B¥ -5.74B¥ -597.72M
Currency in CNY

Innovent Biologics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis